{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:06:50Z","timestamp":1785128810827,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T00:00:00Z","timestamp":1673136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T00:00:00Z","timestamp":1673136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>VEXAS (vacuoles, E1 enzyme, X-linked, auto-inflammatory, somatic) syndrome is a newly described auto-inflammatory disease. Many cases feature pulmonary infiltrates or respiratory failure. This systematic review aimed to summarize respiratory manifestations in VEXAS syndrome described to date.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Databases were searched for articles discussing VEXAS syndrome until May 2022. The research question was: What are the pulmonary manifestations in patients with VEXAS syndrome? The search was restricted to English language and those discussing clinical presentation of disease. Information on basic demographics, type and prevalence of pulmonary manifestations, co-existing disease associations and author conclusions on pulmonary involvement were extracted. The protocol was registered on the PROSPERO register of systematic reviews.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Initially, 219 articles were retrieved with 36 ultimately included (all case reports or series). A total of 269 patients with VEXAS were included, 98.6% male, mean age 66.8\u00a0years at disease onset. The most frequently described pulmonary manifestation was infiltrates (43.1%; <jats:italic>n<\/jats:italic>\u2009=\u2009116), followed by pleural effusion (7.4%; <jats:italic>n<\/jats:italic>\u2009=\u200920) and idiopathic interstitial pneumonia (3.3%; <jats:italic>n<\/jats:italic>\u2009=\u20099). Other pulmonary manifestations were: nonspecific interstitial pneumonia (<jats:italic>n<\/jats:italic>\u2009=\u20091), bronchiolitis obliterans (<jats:italic>n<\/jats:italic>\u2009=\u20093), pulmonary vasculitis (<jats:italic>n<\/jats:italic>\u2009=\u20096), bronchiectasis (<jats:italic>n<\/jats:italic>\u2009=\u20091), alveolar haemorrhage (<jats:italic>n<\/jats:italic>\u2009=\u20091), pulmonary embolism (<jats:italic>n<\/jats:italic>\u2009=\u20094), bronchial stenosis (<jats:italic>n<\/jats:italic>\u2009=\u20091), and alveolitis (<jats:italic>n<\/jats:italic>\u2009=\u20091). Several patients had one or more co-existing autoimmune\/inflammatory condition. It was not reported which patients had particular pulmonary manifestations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This is the first systematic review undertaken in VEXAS patients. Our results demonstrate that pulmonary involvement is common in this patient group. It is unclear if respiratory manifestations are part of the primary disease or a co-existing condition. Larger epidemiological analyses will aid further characterisation of pulmonary involvement and disease management.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00296-022-05266-2","type":"journal-article","created":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T12:02:46Z","timestamp":1673179366000},"page":"1023-1032","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Pulmonary manifestations in VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome: a systematic review"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6276-137X","authenticated-orcid":false,"given":"Koushan","family":"Kouranloo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athea","family":"Ashley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3558-7353","authenticated-orcid":false,"given":"Sizheng Steven","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6858-4338","authenticated-orcid":false,"given":"Mrinalini","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,8]]},"reference":[{"issue":"27","key":"5266_CR1","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","volume":"383","author":"DB Beck","year":"2020","unstructured":"Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W et al (2020) Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med 383(27):2628\u20132638","journal-title":"N Engl J Med"},{"issue":"26","key":"5266_CR2","first-page":"3591","volume":"137","author":"PC Grayson","year":"2021","unstructured":"Grayson PC, Patel BA, Young NS (2021) VEXAS syndrome. Blood 137(26):3591\u20133594","journal-title":"Blood"},{"key":"5266_CR3","doi-asserted-by":"crossref","unstructured":"Jamshidi A, Aslani S, Mahmoudi M (2018) Pulmonary manifestations of autoinflammatory disorders. Pulm Manif Prim Immunodefic Dis 193\u2013211","DOI":"10.1007\/978-3-030-00880-2_7"},{"issue":"7","key":"5266_CR4","first-page":"572","volume":"56","author":"M Gulati","year":"2001","unstructured":"Gulati M, Mani NBS, Singh P, Suri S (2001) Pulmonary manifestations of Beh\u00e7et\u2019s disease. Thorax 56(7):572\u2013578","journal-title":"Thorax"},{"key":"5266_CR5","doi-asserted-by":"publisher","unstructured":"Dubey S, Gelder C, Pink G, Ali A, Taylor C, Shakespeare J, et al. (2021) Respiratory subtype of relapsing polychondritis frequently presents as difficult asthma: a descriptive study of respiratory involvement in relapsing polychondritis with 13 patients from a single UK centre. ERJ Open Res 7(1):00170\u20132020. https:\/\/doi.org\/10.1183\/23120541.00170-2020","DOI":"10.1183\/23120541.00170-2020"},{"issue":"Suppl 1","key":"5266_CR6","doi-asserted-by":"publisher","first-page":"1028.1","DOI":"10.1136\/annrheumdis-2022-eular.5232","volume":"81","author":"M Casal Moura","year":"2022","unstructured":"Casal Moura M, Baqir M, Tandon Y, Samec M, Reichard K, Mangaonkar A et al (2022) POS1377 LUNG INVOLVEMENT IN VEXAS SYNDROME. Ann Rheum Dis 81(Suppl 1):1028.1-1028","journal-title":"Ann Rheum Dis"},{"key":"5266_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.678927","volume":"12","author":"F Staels","year":"2021","unstructured":"Staels F, Betrains A, Woei-A-Jin FJSH, Boeckx N, Beckers M, Bervoets A et al (2021) Case report: VEXAS syndrome: from mild symptoms to life-threatening macrophage activation syndrome. Front Immunol 12:678927","journal-title":"Front Immunol"},{"issue":"3","key":"5266_CR8","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/bjd.20805","volume":"186","author":"S Georgin-Lavialle","year":"2022","unstructured":"Georgin-Lavialle S, Terrier B, Guedon AF, Heiblig M, Comont T, Lazaro E et al (2022) Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients*. Br J Dermatol 186(3):564\u2013574","journal-title":"Br J Dermatol"},{"key":"5266_CR9","doi-asserted-by":"publisher","unstructured":"(2022) A review of VEXAS syndrome in 116 French patients. Br J Dermatol 186: e115\u2013e115. https:\/\/doi.org\/10.1111\/bjd.20989","DOI":"10.1111\/bjd.20989"},{"key":"5266_CR10","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions | Cochrane Training. https:\/\/training.cochrane.org\/handbook\/current. Accessed 31 Aug 2020"},{"key":"5266_CR11","doi-asserted-by":"crossref","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. (2021) PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 372. https:\/\/www.bmj.com\/content\/372\/bmj.n160. Accessed 3 Oct 2021","DOI":"10.1136\/bmj.n160"},{"issue":"10","key":"5266_CR12","doi-asserted-by":"publisher","first-page":"e356","DOI":"10.1093\/rheumatology\/keab349","volume":"60","author":"M Sakuma","year":"2021","unstructured":"Sakuma M, Tanimura A, Yasui S, Ishiguro K, Kobayashi T, Ohshiro Y et al (2021) A Case of polychondritis-onset refractory organizing pneumonia with cytopaenia diagnosed as VEXAS syndrome: the disease course of 7 years. Rheumatology 60(10):e356\u2013e359","journal-title":"Rheumatology"},{"issue":"5","key":"5266_CR13","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s10875-022-01258-w","volume":"42","author":"J Poulter","year":"2022","unstructured":"Poulter J, Gough A, Isaacs JD, Green M, McHugh N, Hordon L et al (2022) A high-throughput amplicon screen for somatic UBA1 variants in cytopenic and giant cell arteritis cohorts. J Clin Immunol 42(5):947\u2013951","journal-title":"J Clin Immunol"},{"issue":"1","key":"5266_CR14","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jaci.2021.05.014","volume":"149","author":"CI van der Made","year":"2022","unstructured":"van der Made CI, Potjewijd J, Hoogstins A, Willems HPJ, Kwakernaak AJ, de Sevaux RGL et al (2022) Adult-onset autoinflammation caused by somatic mutations in UBA1: a Dutch case series of patients with VEXAS. J Allergy Clin Immunol 149(1):432-439.e4","journal-title":"J Allergy Clin Immunol"},{"issue":"26","key":"5266_CR15","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1182\/blood.2020010286","volume":"137","author":"JA Poulter","year":"2021","unstructured":"Poulter JA, Collins JC, Cargo C, De Tute RM, Evans P, Ospina Cardona D et al (2021) Novel somatic mutations in UBA1 as a cause of VEXAS syndrome. Blood 137(26):3676","journal-title":"Blood"},{"issue":"16","key":"5266_CR16","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1182\/bloodadvances.2021004976","volume":"5","author":"IE Obiorah","year":"2021","unstructured":"Obiorah IE, Patel BA, Groarke EM, Wang W, Trick M, Ombrello AK et al (2021) Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1. Blood Adv 5(16):3203\u20133215","journal-title":"Blood Adv"},{"key":"5266_CR17","first-page":"5984","volume":"12","author":"F L\u00f6tscher","year":"2022","unstructured":"L\u00f6tscher F, Seitz L, Simeunovic H, Sarbu AC, Porret NA, Feldmeyer L et al (2022) Case report: genetic double strike: VEXAS and TET2-positive myelodysplastic syndrome in a patient with long-standing refractory autoinflammatory disease. Front 12:5984","journal-title":"Front"},{"issue":"4","key":"5266_CR18","volume":"8","author":"A Himmelmann","year":"2021","unstructured":"Himmelmann A, Br\u00fccker R (2021) The VEXAS syndrome: uncontrolled inflammation and macrocytic anaemia in a 77-year-old male patient. Eur J Case Rep Intern Med 8(4):002484","journal-title":"Eur J Case Rep Intern Med"},{"issue":"10","key":"5266_CR19","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1002\/art.41743","volume":"73","author":"MA Ferrada","year":"2021","unstructured":"Ferrada MA, Sikora KA, Luo Y, Wells KV, Patel B, Groarke EM et al (2021) Somatic mutations in UBA1 define a distinct subset of relapsing polychondritis patients with VEXAS. Arthritis Rheumatol 73(10):1886\u20131895","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"5266_CR20","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/mrcr\/rxab021","volume":"6","author":"F Shaukat","year":"2022","unstructured":"Shaukat F, Hart M, Burns T, Bansal P (2022) UBA1 and DNMT3A mutations in VEXAS syndrome. A case report and literature review. Mod Rheumatol Case Reports. 6(1):134\u2013139","journal-title":"Mod Rheumatol Case Reports."},{"issue":"2","key":"5266_CR21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/art.41957","volume":"74","author":"A Sharma","year":"2022","unstructured":"Sharma A, Naidu G, Deo P, Beck DB (2022) VEXAS syndrome with systemic lupus erythematosus: expanding the spectrum of associated conditions. Arthritis Rheumatol 74(2):369\u2013371","journal-title":"Arthritis Rheumatol"},{"key":"5266_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2021.102636","volume":"93","author":"RL Kao","year":"2022","unstructured":"Kao RL, Jacobsen AA, Billington CJ, Yohe SL, Beckman AK, Vercellotti GM et al (2022) A case of VEXAS syndrome associated with EBV-associated hemophagocytic lymphohistiocytosis. Blood Cells, Mol Dis 93:102636","journal-title":"Blood Cells, Mol Dis"},{"issue":"3","key":"5266_CR23","first-page":"E69","volume":"61","author":"A P\u00e0mies","year":"2022","unstructured":"P\u00e0mies A, Ferr\u00e0s P, Bellaub\u00ed-Pallare N, Gimenez T, Ravent\u00f3s A, Colobran R (2022) VEXAS syndrome: relapsing polychondritis and myelodysplastic syndrome with associated immunoglobulin A vasculitis. Rheumatol (United Kingdom) 61(3):E69-71","journal-title":"Rheumatol (United Kingdom)"},{"issue":"4","key":"5266_CR24","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/art.41992","volume":"74","author":"F Muratore","year":"2022","unstructured":"Muratore F, Marvisi C, Castrignan\u00f2 P, Nicoli D, Farnetti E, Bonanno O et al (2022) VEXAS syndrome: a case series from a single-center cohort of italian patients with vasculitis. Arthritis Rheumatol 74(4):665\u2013670","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"5266_CR25","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1111\/1346-8138.16311","volume":"49","author":"A Matsubara","year":"2022","unstructured":"Matsubara A, Tsuchida N, Sakurai M, Maeda A, Uchiyama Y, Sasaki K et al (2022) A case of VEXAS syndrome with sweet\u2019s disease and pulmonary involvement. J Dermatol 49(5):e177\u2013e178","journal-title":"J Dermatol"},{"issue":"4","key":"5266_CR26","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1080\/03009742.2022.2045791","volume":"51","author":"E Mart\u00edn-Nares","year":"2022","unstructured":"Mart\u00edn-Nares E, Vargas-Seraf\u00edn C, Delgado-de la Mora J, Montante-Montes de Oca D, Grayson PC, Larios E et al (2022) Orbital and periorbital inflammation in VEXAS syndrome. Scand J Rheumatol 51(4):338\u2013341","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"5266_CR27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1182\/bloodadvances.2021005243","volume":"6","author":"P Li","year":"2022","unstructured":"Li P, Venkatachalam S, Cordona DO, Wilson L, Kovacsovics T, Moser KA et al (2022) A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm. Blood Adv 6(2):405\u2013409","journal-title":"Blood Adv"},{"issue":"4","key":"5266_CR28","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/imj.15742","volume":"52","author":"S Islam","year":"2022","unstructured":"Islam S, Cullen T, Sumpton D, Damodaran A, Heath D, Bosco A et al (2022) VEXAS syndrome: lessons learnt from an early Australian case series. Intern Med J 52(4):658\u2013662","journal-title":"Intern Med J"},{"key":"5266_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jdcr.2022.02.022","volume":"23","author":"A Goyal","year":"2022","unstructured":"Goyal A, Narayanan D, Wong W, Laga AC, Connell NT, Ritter SY et al (2022) Tocilizumab for treatment of cutaneous and systemic manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome without myelodysplastic syndrome. JAAD Case Reports 23:15\u201319","journal-title":"JAAD Case Reports"},{"issue":"3","key":"5266_CR30","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1182\/bloodadvances.2021004749","volume":"6","author":"A Diarra","year":"2022","unstructured":"Diarra A, Duployez N, Fournier E, Preudhomme C, Coiteux V, Magro L et al (2022) Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience. Blood Adv 6(3):998\u20131003","journal-title":"Blood Adv"},{"issue":"7","key":"5266_CR31","first-page":"1449","volume":"40","author":"H Cifersk\u00e1","year":"2022","unstructured":"Cifersk\u00e1 H, Gregov\u00e1 M, Klein M, \u0160enolt L, Maaloufov\u00e1 JS, Pavelka K et al (2022) VEXAS syndrome: a report of three cases. Clin Exp Rheumatol 40(7):1449","journal-title":"Clin Exp Rheumatol"},{"key":"5266_CR32","doi-asserted-by":"crossref","unstructured":"Afsahi V, Christensen RE, Alam M. (2022) VEXAS syndrome in dermatology. Arch Dermatol Res. https:\/\/pubmed.ncbi.nlm.nih.gov\/35201420\/. Accessed 26 Sep 2022","DOI":"10.1007\/s00403-022-02340-4"},{"issue":"6","key":"5266_CR33","doi-asserted-by":"publisher","first-page":"274","DOI":"10.14740\/jh940","volume":"10","author":"VT Thomas","year":"2021","unstructured":"Thomas VT, Penmetcha M (2021) Myelodysplastic syndrome associated with auto-immune inflammatory disease in VEXAS syndrome. J Hematol 10(6):274","journal-title":"J Hematol"},{"issue":"10","key":"5266_CR34","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1002\/art.41775","volume":"73","author":"N Takahashi","year":"2021","unstructured":"Takahashi N, Takeichi T, Nishida T, Sato J, Takahashi Y, Yamamura M et al (2021) Extensive multiple organ involvement in VEXAS syndrome. Arthritis Rheumatol (Hoboken, NJ) 73(10):1896\u20131897","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"7","key":"5266_CR35","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1007\/s10875-021-01070-y","volume":"41","author":"A Grey","year":"2021","unstructured":"Grey A, Cheong PL, Lee FJ, Abadir E, Favaloro J, Yang S et al (2021) A case of VEXAS syndrome complicated by hemophagocytic lymphohistiocytosis. J Clin Immunol 41(7):1648\u20131651","journal-title":"J Clin Immunol"},{"issue":"23","key":"5266_CR36","doi-asserted-by":"publisher","first-page":"5586","DOI":"10.3390\/jcm10235586","volume":"10","author":"M Delplanque","year":"2021","unstructured":"Delplanque M, Aouba A, Hirsch P, Fenaux P, Graveleau J, Malard F et al (2021) USAID associated with myeloid neoplasm and VEXAS syndrome: two differential diagnoses of suspected adult onset still\u2019s disease in elderly patients. J Clin Med 10(23):5586","journal-title":"J Clin Med"},{"issue":"10300","key":"5266_CR37","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0140-6736(21)01430-6","volume":"398","author":"N Dehghan","year":"2021","unstructured":"Dehghan N, Marcon KM, Sedlic T, Beck DB, Dutz JP, Chen LYC (2021) Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome: fevers, myalgia, arthralgia, auricular chondritis, and erythema nodosum. Lancet 398(10300):621","journal-title":"Lancet"},{"key":"5266_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.108996","volume":"238","author":"H Matsumoto","year":"2022","unstructured":"Matsumoto H, Asano T, Tsuchida N, Maeda A, Yoshida S, Yokose K et al (2022) Beh\u00e7et\u2019s disease with a somatic UBA1 variant: Expanding spectrum of autoinflammatory phenotypes of VEXAS syndrome. Clin Immunol 238:108996","journal-title":"Clin Immunol"},{"issue":"2","key":"5266_CR39","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41409-021-01544-y","volume":"57","author":"M Loschi","year":"2022","unstructured":"Loschi M, Roux C, Sudaka I, Ferrero-Vacher C, Marceau-Renaut A, Duployez N et al (2022) Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: a case report. Bone Marrow Transplant 57(2):315\u2013318","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"5266_CR40","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s11239-021-02608-y","volume":"53","author":"TM Oo","year":"2022","unstructured":"Oo TM, Koay JTJ, Lee SF, Lee SMS, Lim XR, Fan BE (2022) Thrombosis in VEXAS syndrome. J Thromb Thrombolysis 53(4):965\u2013970","journal-title":"J Thromb Thrombolysis"},{"issue":"9","key":"5266_CR41","doi-asserted-by":"publisher","first-page":"E304","DOI":"10.1093\/rheumatology\/keab200","volume":"60","author":"SMS Lee","year":"2021","unstructured":"Lee SMS, Fan BE, Lim JHL, Goh LL, Lee JSS, Koh LW (2021) A case of VEXAS syndrome manifesting as Kikuchi-Fujimoto disease, relapsing polychondritis, venous thromboembolism and macrocytic anaemia. Rheumatology (Oxford) 60(9):E304\u2013E306","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"5266_CR42","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1001\/jamaoto.2021.4092","volume":"148","author":"S Beaumesnil","year":"2022","unstructured":"Beaumesnil S, Boucher S, Lavigne C, Urbanski G, Lacombe V (2022) Ear, nose, throat, and bronchial involvements in VEXAS syndrome: specifying the spectrum of clinical features. JAMA Otolaryngol Neck Surg 148(3):284\u2013286","journal-title":"JAMA Otolaryngol Neck Surg"},{"issue":"8","key":"5266_CR43","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1136\/annrheumdis-2021-220089","volume":"80","author":"N Tsuchida","year":"2021","unstructured":"Tsuchida N, Kunishita Y, Uchiyama Y, Kirino Y, Enaka M, Yamaguchi Y et al (2021) Pathogenic UBA1 variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis. Ann Rheum Dis 80(8):1057\u20131061","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"5266_CR44","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1001\/jamadermatol.2021.3344","volume":"157","author":"E Zakine","year":"2021","unstructured":"Zakine E, Schell B, Battistella M, Vignon-Pennamen MD, Chasset F, Mah\u00e9vas T et al (2021) UBA1 variations in neutrophilic dermatosis skin lesions of patients with VEXAS syndrome. JAMA Dermatol 157(11):1349\u20131354","journal-title":"JAMA Dermatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05266-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-022-05266-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05266-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T16:03:24Z","timestamp":1682352204000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-022-05266-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,8]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["5266"],"URL":"https:\/\/doi.org\/10.1007\/s00296-022-05266-2","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,8]]},"assertion":[{"value":"9 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors KK, AA, SZ and MD declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}